Navitoclax clinical trials
Navitoclax is named as an intervention in 6 current clinical trials in our USA, Spain, Italy, Sweden, Turkey, Japan, Australia, Israel, UK, China, Germany, France, Belgium, Taiwan, Canada, South Korea, Denmark, Poland, Switzerland, Austria, Czechia and Brazil registers. None are recruiting at the moment. The most common phase is Phase 1. The sponsor with the most trials is AbbVie (3). The most-studied condition is Myelofibrosis (MF).
Where Navitoclax is approved
All regulators →- 1 EU orphan designation, most recently for treatment of myelofibrosis (16 Dec 2019, withdrawn)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Navitoclax works
All drug targets →- Apoptosis regulator Bcl-2 inhibitor InhibitorTarget: BCL2 BCL2 apoptosis regulator✓ In ChEMBL and the Guide to Pharmacology
- Apoptosis regulator Bcl-X inhibitor InhibitorTarget: BCL2L1 BCL2 like 1✓ In ChEMBL and the Guide to Pharmacology
- Apoptosis regulator Bcl-W inhibitor InhibitorTarget: Bcl-2-like protein 2ChEMBL only
- MyelofibrosisPhase 3
- B-cell chronic lymphocytic leukemiaPhase 2
- Acute lymphoblastic leukemiaPhase 2
- Diffuse large B-cell lymphomaPhase 2
- Lymphoblastic lymphomaPhase 2
- Mantle cell lymphomaPhase 2
- Ovarian cancerPhase 2
- Prostate cancerPhase 2
- Lymphoid neoplasmPhase 1/2
- LymphomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL443684, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 8319, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Navitoclax
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Navitoclax
- ChEMBL
- CHEMBL443684
- DrugBank
- DB12340
- PubChem CID
- 24978538
- CAS number
- 923564-51-6
- FDA UNII
- XKJ5VVK2WD
- Wikidata
- Q18002993
- Wikipedia
- Navitoclax
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Navitoclax
6 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Navitoclax
10 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbbVie | 3 |
| Sunnybrook Health Sciences Centre | 1 |
| Peter MacCallum Cancer Centre, Australia | 1 |
| Jacqueline Garcia, MD | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Navitoclax trials
How many clinical trials are testing Navitoclax?
6 current trials in our USA, Spain, Italy, Sweden, Turkey, Japan, Australia, Israel, UK, China, Germany, France, Belgium, Taiwan, Canada, South Korea, Denmark, Poland, Switzerland, Austria, Czechia and Brazil registers name Navitoclax (also registered as ABT-263) as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.
Are Navitoclax trials recruiting patients?
Not at the moment. None of the 6 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors Navitoclax clinical trials?
AbbVie (3), Sunnybrook Health Sciences Centre (1), Peter MacCallum Cancer Centre, Australia (1) and Jacqueline Garcia, MD (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Navitoclax works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Navitoclax works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Navitoclax (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.